Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428749 | 1.00 | CCNB2 (0.52) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL430374 | 0.85 | NPC1 (0.49) | L3MBTL1MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11940501 | 0.85 | PTGDR2 (0.46) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL20767525 | 0.85 | CCNB2 (0.58) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL8687875 | 0.82 | CCNB2 (0.55) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL7396646 | 0.82 | MAOA (0.46) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL20690103 | 0.82 | HPGD (0.46) | L3MBTL1MAPTMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7165848 | 0.80 | CCNB2 (0.44) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL7165851 | 0.80 | CCNB2 (0.44) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL9985970 | 0.80 | MRGPRX4 (0.50) | L3MBTL1MAPTALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249706-A | Preparation method of intermediate for synthesizing prostacyclin derivative | 常州方圆制药有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-20250002442-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240287105-A1 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | UNITED THERAPEUTICS CORPORATION (US) | 2024-08-29 | — | — | US | disclosed |
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
| EP-3700911-B1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2022-07-07 | — | — | US | disclosed |
| CN-114249706-A | Preparation method of intermediate for synthesizing prostacyclin derivative | 常州方圆制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| EP-2576492-A1 | TREPROSTINIL PRODUCTION | United Therapeutics Corporation (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120226076-A1 | SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION | 2012-09-06 | — | — | US | disclosed |
| US-20120226076-A1 | SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION | 2012-09-06 | — | — | US | disclosed |
| US-20120197041-A1 | TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120190888-A1 | TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION | 2012-07-26 | — | — | US | disclosed |
| US-20110319641-A1 | TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION | 2011-12-29 | — | — | US | disclosed |
| WO-2011153363-A1 | TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20040176645-A1 | Process for stereoselective synthesis of prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6569894-B1 | Such as N-(3-(2-(4-phenylbutyl)-2,3-dihydrobenzofuran-4-yl)propyl)acetamide for treating circadian rhythm-related disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-27 | — | — | US | disclosed |
| US-20020099034-A1 | Process for stereoselective synthesis of prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGES | CCNB2 2223/4885CDK1 1125/4885CDK4 2029/4885 |
| US-20120190888-A1 | TREPROSTINIL PRODUCTION | PTGIS, PTGIR, PTGES | CCNB2 3210/4885CDK1 1520/4885CDK4 1700/4885 |
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | CCNB2 127/4885CDK1 274/4885CDK4 411/4885 |
| US-20020099034-A1 | Process for stereoselective synthesis of prostacyclin derivatives | PTGIS, PTGES, PTGIR | CCNB2 3657/4885CDK1 2703/4885CDK4 2867/4885 |
| US-20240287105-A1 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | TYMP, TTPA, PTGIS | CCNB2 2605/4885CDK1 1849/4885CDK4 1952/4885 |
| US-20110319641-A1 | TREPROSTINIL PRODUCTION | PTGIS, PTGIR, PTGES | CCNB2 3182/4885CDK1 1765/4885CDK4 1656/4885 |
| US-20120197041-A1 | TREPROSTINIL PRODUCTION | PTGIS, PTGIR, PTGES | CCNB2 3210/4885CDK1 1520/4885CDK4 1700/4885 |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGS2 | CCNB2 447/4885CDK1 607/4885CDK4 2065/4885 |
| US-20250002442-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | CCNB2 2223/4885CDK1 1125/4885CDK4 2029/4885 |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | CCNB2 2223/4885CDK1 1125/4885CDK4 2029/4885 |
| US-20040176645-A1 | Process for stereoselective synthesis of prostacyclin derivatives | PTGIS, PTGES, PTGIR | CCNB2 3657/4885CDK1 2703/4885CDK4 2867/4885 |
| US-20120226076-A1 | SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION | PTGIS, PTGES, TBXAS1 | CCNB2 2382/4885CDK1 1041/4885CDK4 2040/4885 |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | CCNB2 2223/4885CDK1 1125/4885CDK4 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.